It will take a ‘few years’ for Sun Pharma to realise the benefits of its $4 billion takeover of Ranbaxy, said the company's Chairman Israel Makov, terming the deal as a ‘complex and large acquisition’. Sun will leverage on complementary functional strengths to achieve topline growth and gains through both revenue enhancement and operational synergies, translating into higher margins, greater market share and more profits through the takeover of Ranbaxy, he said. "Ranbaxy ... Rediff.com, 2 months ago
The condition of divestment of 7 products by antitrust regulator Competition Commission of India (CCI) for the merger of Sun Pharmaceutical Industries, a Rs. 16,000 crore Indian pharma giant and Ranbaxy Laboratories, a Rs. 13,000 crore plus ...PharmaBiz, 4 days ago
Plunkett's Manufacturing & Robotics Industry Almanac 2015: Manufacturing & Robotics Industry Market Research, Statistics, Trends & Leading Companies
PLUNKETTS MANUFACTURING & ROBOTICS INDUSTRY ALMANAC 2015 Key Findings: Plunkett Research lists top 500 companies in Manufacturing & Robotics and names top trends changing the industry for the mid term Key Features: Industry trends analysis, market ...MarketResearch.com, 3 weeks ago
Plunkett's Biotech & Genetics Industry Almanac 2015: Biotech & Genetics Industry Market Research, Statistics, Trends & Leading Companies
PLUNKETT'S BIOTECH & GENETICS INDUSTRY ALMANAC 2015 Key Findings: Plunkett Research lists top 400 companies in the Biotech & Genetics and names top trends changing the industry for the mid term. Key Features:Industry trends analysis, market data ...MarketResearch.com, 1 month ago
on your WebpageAdd Widget >Get your members hooked!